| Literature DB >> 26935022 |
Xiaofeng Tang1, Jianjun Tang2, Xia Liu3, Lei Zeng4, Chun Cheng1, Yanqin Luo1, Liping Li1, Shu-Lan Qin1, Yi Sang1, Liang-Ming Deng5, Xiao-Bin Lv1.
Abstract
Aberrant expression of the miR-129 family has been found in several types of cancer, yet its expression and potential biologic role in breast cancer remain largely unknown. In the present study, we found that miR-129-2 was consistently downregulated in the breast cancer specimens and cell lines. Overexpression of miR-129-2-3p markedly suppressed breast cancer cell proliferation and induced its apoptosis. In addition, a luciferase reporter assay revealed that miR-129-2-3p suppressed BCL2L2 expression. Furthermore, BCL2L2 was able to reverse miR-129-2-3p-mediated cell apoptosis, indicating that BCL2L2 plays a crucial role in mediating the tumor-suppressive role of miR-129-2-3p. Moreover, bisulfite DNA sequencing PCR (BSP) analysis identified that promoter hypermethylation was responsible for the downregulation of miR-129-2 in breast cancer. Collectively, our findings indicate that miR-129-2 is downregulated in breast cancer cells by promoter hypermethylation. Moreover, downregulation of miR-129-2 results in BCL2L2 overexpression and disease progression in breast cancer patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26935022 DOI: 10.3892/or.2016.4647
Source DB: PubMed Journal: Oncol Rep ISSN: 1021-335X Impact factor: 3.906